![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The International Conference on Inflammopharmacology with VIII Side-Effects of Anti-Inflammatory Drugs Symposium was held in Edinburgh, UK on 22 – 24 April 2003. The meeting was well attended, involving ~ 80 rheumatologists, pharmacologists and research scientists from both academia and industry with a special interest in osteoarthritis. Although few new drugs emerged at the meeting as treatment options for osteoarthritis, exciting data on the latest advances in novel inhibitors of the pathways involved in the pathogenesis of osteoarthritis were presented. This report describes recent clinical experiences with the unique lipoxygenase/cyclooxygenase inhibitor licofelone (ML3000; EuroAlliance, a partnership of Merckle [Germany], Alfa Wassermann [Italy] and Lácer [Spain]) and the latest developments in nitric oxide-donating non-steroidal anti-inflammatory drugs NMI-1093 and NMI1089 (Nitromed, Inc., USA) and AZD3582 (AstraZeneca, Sweden).